Rani Therapeutics’ (RANI) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. Separately, Canaccord Genuity Group reissued a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a […]
HC Wainwright restated their buy rating on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. Separately, Canaccord Genuity Group reissued a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a […]
